BIOMUNEX Pharmaceuticals is a biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform. In particular, BIOMUNEX is developing a disruptive biological approach, the so-called BiXAb-MAIT engagers, that redirect MAIT cells to kill cancer cells, and can become a true game changer in the treatment of cancer patients. To know more
